← Open Payments lookup

NPI 1306365689: Open Payments

NPI 1306365689. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,207 in 57 payments from 11 companies in 2025. Trend: 2023 $754 · 2024 $517 · 2025 $1,207

Food & beverage: $1,207
CompanyPaymentsAmount
Otsuka America Pharmaceutical, Inc.13$239
ABBVIE INC.7$218
Vanda Pharmaceuticals Inc.8$180
Neurocrine BioSciences, Inc.5$146
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)10$143
Axsome Therapeutics, Inc.4$92
Lundbeck LLC4$70
Sage Therapeutics, LLC2$48
Teva Pharmaceuticals USA, Inc.2$35
Alkermes, Inc.1$18

Products named: VRAYLAR, REXULTI, HETLIOZ, INGREZZA, CAPLYTA, ABILIFY MAINTENA, Auvelity, ZURZUVAE.